The purpose of this study is to compare CT perfusion parameters to RECIST 1.1 and mRECIST assessment for advanced HCC treated by systemic immunotherapy, and to evaluate perfusion parameters as predictive factors of response on baseline and on early follow-up

Inclusion Criteria:

• Patients > 18 years old
• Proved HCC
• Advanced HCC, defined as Barcelona Clinic Liver Classifications (BCLC) stage B non eligible for loco-regional therapy and stage C
• No prior systemic therapy
• Measurable disease per Response Evaluation Criteria for Solid Tumour (RECIST) v1.1
• Child-Pugh Score = A
• Eastern Cooperative Oncology Group (ECOG) Performance Status < 2

Exclusion Criteria:

• Absence of CT perfusion before treatment initiation more than a two-month delay between treatment initiation and first post-treatment CT perfusion
• Uninterpretable CT perfusion
• Definitive contraindication to CT perfusion (allergy or advanced renal disease)

HepatoCellular Carcinoma (HCC) treated by systemic immunotherapy